Clinical and Laboratory ObservationLightwood Syndrome Revisited with a Novel Mutation in CYP24 and Vitamin D Supplement Recommendations
Section snippets
Case Report
The index case, one of the twins, was born at 36 weeks gestation and treated with vitamin D (400 IU from fortified milk formula + 1500 IU supplementation because of prematurity). He presented at 6 months of age with vomiting and failure to thrive. He had severe hypercalcemia (3.68 mmol/L, normal value < 2.6) with low serum level PTH at 1 ng/L (normal value 10-55), slightly elevated serum level 25 (OH) D at 140 nmol/L, normal serum level of 1,25(OH)2D at 96 pmol/L (normal value 60-120), and
Discussion
This case illustrates the genotype/phenotype correlation with the CYP24A1 mutation together with a variable response to the dose of vitamin D supplementation. In the twins who received the same high vitamin D supplementation, it was only the child homozygous for the mutation who exhibited hypercalcemia, hypercalciuria, and resulting nephrocalcinosis (IIH). Conversely, in the 2 brothers with the same mutation, it was only the child who received high vitamin D supplementation who developed IIH.
References (8)
- et al.
Idiopathic hypercalcemia in infants
Lancet
(1953) - et al.
Infantile hypercalcemia and hypercalciuria: new insights into a vitamin D-dependent mechanism and response to ketoconazole treatment
J Pediatr
(2010) - et al.
Calcium metabolism in Williams-Beuren syndrome
J Pediatr
(1992) - et al.
Vitamin D: still a topical matter in children and adolescents. A position paper by the Committee on Nutrition of the French Society of Pediatrics
Arch Pediatr
(2012)
Cited by (0)
The authors declare no conflicts of interest.